62,978 results match your criteria Neutropenia


Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia.

Am J Clin Oncol 2018 Dec 14. Epub 2018 Dec 14.

Department of Obstetrics and Gynecology, Section of Gynecologic Oncology.

Background: The Multinational Association of Supportive Care of Cancer (MASCC) risk-index score has been validated as a stratification tool for febrile neutropenia (FN) risk in a heterogeneous group of cancer patients; recently, it has been deemed a suitable tool in gynecologic oncology patients in a retrospective study. This is a prospective multi-institutional study wherein we sought to validate MASCC score for stratifying FN morbidity in gynecologic oncology patients.

Methods: IRB approval was obtained at 4 institutions for prospective data collection of gynecologic cancer patients admitted with FN from 3/1/2013 to 9/1/2014. Read More

View Article
December 2018

Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR.

Curr Med Res Opin 2018 Dec 17:1-27. Epub 2018 Dec 17.

i Gynecological Center Bonn-Friedensplatz , Bonn , Germany.

Objectives: The non-interventional study (NIS) NADIR (DRKS00005711) evaluated the effectiveness and safety of prophylaxis with lipegfilgrastim, a glycopegylated granulocyte-colony stimulating factor, in 2500 patients undergoing chemotherapy in routine clinical practice. Primary objective was the incidence of chemotherapy-induced severe neutropenia, febrile neutropenia (FN) and neutropenia-associated complications.

Methods: NADIR was a prospective NIS conducted in 201 study centers in Germany. Read More

View Article
December 2018

Cannabinoid CB Receptor Antagonist Rimonabant Decreases Levels of Markers of Organ Dysfunction and Alters Vascular Reactivity in Aortic Vessels in Late Sepsis in Rats.

Inflammation 2018 Dec 17. Epub 2018 Dec 17.

Department of Pharmacology, Biological Sciences Section, Federal University of Paraná, Curitiba, Paraná, Brazil.

Sepsis is a life-threatening condition with high mortality rates that is caused by dysregulation of the host response to infection. We previously showed that treatment with the cannabinoid CB receptor antagonist rimonabant reduced mortality rates in animals with sepsis that was induced by cecal ligation and puncture (CLP). This improvement in the survival rate appeared to be related to an increase in arginine vasopressin (AVP) levels 12 h after CLP. Read More

View Article
December 2018

Immune cell counts and signaling in body fluids of cows vaccinated against .

J Biol Res (Thessalon) 2018 Dec 10;25:20. Epub 2018 Dec 10.

Chair of Animal Physiology and Immunology, Technical University of Munich (TUM), Weihenstephaner Berg 3, 85354 Freising, Germany.

Background: New treatment options are needed to prevent relapses following failed antibiotic therapies of infections (CDI) in humans. The concomitant therapy with an anti- IgA containing whey protein concentrate can support the sustainable recovery of CDI patients. For 31 weeks, nine dairy cows were continuously vaccinated with several anti- vaccines by certain routes of administration to produce anti- IgA enriched milk. Read More

View Article
December 2018

Fatal Invasive Pulmonary Aspergillosis Associated with Nonspecific Interstitial Pneumonia: An Autopsy Case Report.

Intern Med 2018 15;57(24):3619-3624. Epub 2018 Dec 15.

Department of Respiratory Medicine, Toho University Omori Medical Center, Japan.

Invasive pulmonary aspergillosis (IPA) usually occurs in patients with severe immunodeficiencies involving neutropenia. Underlying lung disease is a well-known risk factor of IPA; however, interstitial lung disease has not been recognized as a risk factor of IPA. We herein report a patient with fibrotic nonspecific interstitial pneumonia who experienced IPA without neutropenia. Read More

View Article
December 2018

Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis.

Ann Rheum Dis 2018 Dec 14. Epub 2018 Dec 14.

Immunology Development, AbbVie, North Chicago, Illinois, USA.

Objective: To assess the efficacy, safety, pharmacokinetics and pharmacodynamics of the anti-interleukin (IL)-1α/β dual variable domain immunoglobulin lutikizumab (ABT-981) in erosive hand osteoarthritis (HOA).

Methods: Patients with ≥1 erosive and ≥3 tender and/or swollen hand joints were randomised to placebo or lutikizumab 200 mg subcutaneously every 2 weeks for 24 weeks. The primary endpoint was change in Australian/Canadian Osteoarthritis Hand Index (AUSCAN) pain subdomain score from baseline to 16 weeks. Read More

View Article
December 2018

Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial.

Oncologist 2018 Dec 14. Epub 2018 Dec 14.

Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.

Lessons Learned: First trial to report safety and activity of the microtubule inhibitor vinflunine plus the tyrosine kinase inhibitor sorafenib in post-platinum metastatic urothelial cancer (mUC) patients.A recommended phase II dose was identified for the treatment combination of vinflunine plus sorafenib, with main adverse events including fatigue, febrile neutropenia, neutropenia, hypertension, and hyponatremia.An overall response rate of 41% to second-line vinflunine plus sorafenib treatment in patients with platinum-resistant mUC was confirmed. Read More

View Article
December 2018
1 Read

Wild edible onions - Allium flavum and Allium carinatum - successfully prevent adverse effects of chemotherapeutic drug doxorubicin.

Biomed Pharmacother 2019 Jan 1;109:2482-2491. Epub 2018 Dec 1.

University of Belgrade, Faculty of Biology, Studentski trg 16, 11000 Belgrade, Serbia.

The objective of this study was to evaluate potential of two chemically characterized edible wild onion species, Allium flavum and Allium carinatum, to reduce side effects of cytostatic doxorubicin (Dox). Since Dox application is mainly limited due to its high cardiotoxicity, while there are no approved cardioprotective agents for the prevention of Dox adverse effects, new co-treatments are urgently needed. Here, we showed that methanol extracts expressed high antioxidant activity and synergistically increased Dox anticancer activity against human hepatoma (HepG2) and lung carcinoma (A549) cells, while protected normal human fibroblasts (MRC-5) from Dox cytotoxicity. Read More

View Article
January 2019
1 Read

Risk factors for death among patients with Chikungunya virus infection during the outbreak in northeast Brazil, 2016-2017.

Trans R Soc Trop Med Hyg 2018 Dec 14. Epub 2018 Dec 14.

Post-Graduation Program in Medical Sciences, Department of Internal Medicine, Federal University of Ceará-UFC. Fortaleza, Ceará, Brazil.

Background: Chikungunya virus (CHIKV) infection is a current public health problem. The aim of this study was to investigate risk factors for death among patients with CHIKV infection during a large epidemic in northeast Brazil.

Methods: This is a cross-sectional study with all registered cases of CHIKV in Ceara, Brazil, during 2016-2017. Read More

View Article
December 2018
1 Read

Safety of endoscopy in cancer patients with thrombocytopenia and neutropenia.

Gastrointest Endosc 2018 Dec 11. Epub 2018 Dec 11.

The University of Texas MD Anderson Cancer Center, Department of Gastroenterology, Hepatology and Nutrition. Electronic address:

Background And Aims: Cancer patients are prone to thrombocytopenia and neutropenia, which increase the risk of bleeding and infection. We assessed the safety of endoscopic procedures in cancer patients with thrombocytopenia and/or neutropenia.

Methods: We studied consecutive cancer patients with thrombocytopenia and/or neutropenia who underwent endoscopic procedures from 2010 through 2015. Read More

View Article
December 2018
3 Reads

Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010-2016: a longitudinal assessment.

Curr Med Res Opin 2018 Dec 14:1-15. Epub 2018 Dec 14.

b Amgen Inc. , Thousand Oaks , CA.

Background: Guidelines recommend primary prophylactic use of colony-stimulating factor (PP-CSF) when risk of febrile neutropenia (FN)-based on chemotherapy and patient risk factors-is high. Whether and how PP-CSF use may have changed over time (e.g. Read More

View Article
December 2018

Mask Off? Lithium Augmentation for Clozapine Rechallenge After Neutropenia or Agranulocytosis: Discontinuation Might Be Risky.

Prim Care Companion CNS Disord 2018 Nov 29;20(6). Epub 2018 Nov 29.

PSTAR Clinic, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA.

View Article
November 2018

Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.

Cancer 2018 Dec 12. Epub 2018 Dec 12.

Department of Public Health Sciences, The University of Chicago, Chicago, Illinois.

Background: Granulocyte colony-stimulating factors (G-CSFs), which are used for the prevention of complications from chemotherapy-related neutropenia, are linked to the risk of developing second primary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The objective of this study was to examine the correlation between using a specific G-CSF agent and the risk of MDS/AML among older patients with non-Hodgkin lymphoma (NHL).

Methods: This was a retrospective cohort study of adults aged >65 years who were diagnosed with first primary NHL between 2001 and 2011. Read More

View Article
December 2018

Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer.

Invest New Drugs 2018 Dec 14. Epub 2018 Dec 14.

Institut Claudius Regaud, IUCT-Oncopole, Departement d'Oncologie Medicale, Toulouse, France.

Purpose To determine the maximum tolerated dose (MTD) of F14512, a topoisomerase II inhibitor designed to target cancer cells through the polyamine transport system, (three-hour daily infusion given for 3 consecutive days every 3 weeks) in platinum-refractory or resistant ovarian cancer. Other objectives were safety, pharmacokinetics (PK), PK/pharmacodynamics relationship, and efficacy. Methods This was an open-label, dose-escalation, multicenter phase I study. Read More

View Article
December 2018

Effectiveness and safety of the pre-prescription of garenoxacin in comparison to moxifloxacin for low-risk febrile neutropenia in breast cancer patients undergoing adjuvant and neoadjuvant chemotherapy.

Support Care Cancer 2018 Dec 13. Epub 2018 Dec 13.

Department of Pharmacy, Osaka City University Hospital, 1-5-7 Asahi-machi, Abeno-ku, Osaka, 545-8586, Japan.

Purpose: The purpose of this study was to compare the efficacy of the pre-prescription of garenoxacin mesylate hydrate (GRNX) with that of moxifloxacin hydrochloride (MFLX) in the management of breast cancer patients with low-risk febrile neutropenia.

Methods: Data from female patients who had been instructed to take previously prescribed oral GRNX or MFLX for 3 days during adjuvant and neoadjuvant chemotherapy if their body temperature exceeded 38 °C were analyzed. This study compared the effectiveness between these fluoroquinolones using a propensity score matching analysis. Read More

View Article
December 2018
1 Read

Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study.

Eur J Nucl Med Mol Imaging 2018 Dec 13. Epub 2018 Dec 13.

Oncology Division, Rambam Health Care Campus, 8 Ha'Aliya Hashniya, and Technion - Israel Institute of Technology, 1 Efron Street, Haifa, Israel.

Purpose: Concomitant treatment with radium-223 and paclitaxel is a potential option for cancer patients with bone metastases; however, myelosuppression risk during coadministration is unknown. This phase Ib study in cancer patients with bone metastases evaluated the safety of radium-223 and paclitaxel.

Methods: Eligible patients had solid tumor malignancies with ≥2 bone metastases and were candidates for paclitaxel. Read More

View Article
December 2018

Predictors of thrombosis in testicular cancer during platinum-based chemotherapy.

World J Urol 2018 Dec 13. Epub 2018 Dec 13.

Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University Hospital Cologne, Kerpener Straße 62, 50937, Cologne, Germany.

Purpose: To identify potential risk factors for the development of venous thromboembolic events in testicular cancer patients receiving platinum-based chemotherapy.

Methods: We performed a retrospective analysis including 255 patients with testicular germ cell tumors who received platinum-based chemotherapy from 2003 to 2018 as a multi-center observational cohort study. Patient and tumor characteristics of patients with and without a thromboembolic event were analyzed. Read More

View Article
December 2018

Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors.

Mol Clin Oncol 2018 Dec 1;9(6):635-639. Epub 2018 Oct 1.

Department of Oncology, University of Florence, I-50134 Florence, Italy.

The majority of patients with ovarian cancer will experience relapse and thus require second-line therapy. While platinum-based therapies are the primary treatments for refractory disease other options are required, particularly for those with partially platinum-sensitive disease as their response rates are lower. Agents that can resensitize relapsed ovarian cancers to platinum, including trabectedin, are therefore of increasing interest. Read More

View Article
December 2018

Adjusted Chemotherapy According to Frailty Status in Elderly Patients With Diffuse Large B-Cell Lymphoma: Experience From a Single Referral Center in Mexico City.

Clin Lymphoma Myeloma Leuk 2018 Nov 17. Epub 2018 Nov 17.

Hematology and Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

Background: Chemotherapy is associated with significant toxicity in elderly patients treated for hematological malignancies. Adequate tools to identify the best tailored treatment are essential.

Patients And Methods: Medical charts of patients treated with adjusted chemotherapy for diffuse large B-cell lymphoma according to frailty status between August 1, 2013 and June 30, 2016 were included. Read More

View Article
November 2018

The incidence, risk factors and outcomes of early bloodstream infection in patients with malignant hematologic disease after unrelated cord blood transplantation: a retrospective study.

BMC Infect Dis 2018 Dec 13;18(1):654. Epub 2018 Dec 13.

Department of Hematology of Anhui Provincial Hospital, Anhui Medical University, 17 Lujiang Road, Hefei, 230001, Anhui, China.

Background: Bloodstream infection (BSI) is one of the major causes of morbidity and mortality for patients undergoing hematopoietic stem cell transplantation (HSCT). The unrelated cord blood transplantation (UCBT) can provided opportunities for patients without suitable donors for bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT), while few studies have addressed BSI after UCBT. The aim of this study was to analyse the incidence and risk factors of BSI, causative organisms, microbial resistance, and its impact on the clinical outcomes and survival of patients. Read More

View Article
December 2018

Unresolved Splenomegaly in Recently Resettled Congolese Refugees - Multiple States, 2015-2018.

MMWR Morb Mortal Wkly Rep 2018 12 14;67(49):1358-1362. Epub 2018 Dec 14.

In 2014, panel physicians from the International Organization for Migration (IOM), who conduct Department of State-required predeparture examinations for U.S.-bound refugees at resettlement sites in Uganda, noticed an unusually high number of Congolese refugees with enlarged spleens, or splenomegaly. Read More

View Article
December 2018

Diagnostic workup in front of an adult neutropenia.

Ann Biol Clin (Paris) 2018 Dec;76(6):651-658

Service de médecine interne, Centre hospitalier de Royan, Vaux-sur-mer, France, Groupement de coopération sanitaire de Saintonge, Laboratoire inter-hospitalier de biologie médicale, Centres hospitaliers de Saint-Jean-d'Angély, Saintes, Royan et Jonzac, Saint-Jean-d'Angély.

Adult neutropenia, defined as a blood neutrophil count below 1.5 G/L, is a common condition. The most common cause of acute neutropenia is a drug-related reaction or an acute infectious disease. Read More

View Article
December 2018

Biomodulatory Treatment With Azacitidine, All- Retinoic Acid and Pioglitazone Induces Differentiation of Primary AML Blasts Into Neutrophil Like Cells Capable of ROS Production and Phagocytosis.

Front Pharmacol 2018 27;9:1380. Epub 2018 Nov 27.

Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany.

Effective and tolerable salvage therapies for elderly patients with chemorefractory acute myeloid leukemia (AML) are limited and usually do not change the poor clinical outcome. We recently described in several chemorefractory elderly AML patients that a novel biomodulatory treatment regimen consisting of low-dose azacitidine (AZA) in combination with PPARγ agonist pioglitazone (PGZ) and all- retinoic acid (ATRA) induced complete remission of leukemia and also triggered myeloid differentiation with rapid increase of peripheral blood neutrophils. Herein, we further investigated our observations and comprehensively analyzed cell differentiation in primary AML blasts after treatment with ATRA, AZA, and PGZ . Read More

View Article
November 2018

FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia.

Clin Cancer Res 2018 Dec 12. Epub 2018 Dec 12.

Office of Oncology Drug Products, United States Food and Drug Administration.

On August 3, 2017, the Food and Drug Administration (FDA) granted regular approval to Vyxeos (also known as CPX-351), a liposomal formulation of daunorubicin and cytarabine in a fixed combination, for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Approval was based on data from Study CLTR0310-301, a randomized, multicenter, open-label, active-controlled trial comparing Vyxeos to a standard combination of daunorubicin and cytarabine ("7+3") in 309 patients 60-75 years of age with newly-diagnosed t-AML or AML-MRC. Due to elemental copper concerns with the Vyxeos formulation, patients with Wilson's disease were excluded from the study. Read More

View Article
December 2018

Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation - a Case Report.

Klin Onkol 2018 ;31(5):380-383

Introduction: Exon 18-T719X EGFR mutation in non-small cell lung cancer is rare, only 1-5% of all EGFR mutations. The efficacy of EGFR tyrosin kinase inhibitors in tumours with uncommon mutations is still unclear and the prediction of response of such tumours to therapy remains unexplored.

Case: A 71-year-old woman with no previous smoking history with disseminated lung adenocarcinoma with exon 18-T719X EGFR mutation was treated with afatinib. Read More

View Article
January 2018

: An emerging tick-borne disease of importance in Canada.

IDCases 2018 28;14:e00472. Epub 2018 Nov 28.

Rady Faculty of Health Sciences, Max Rady College of Medicine, Department of Internal Medicine, Section of Medical Oncology and Hematology, University of Manitoba, Winnipeg, MB, Canada.

Human Granulocytic Anaplasmosis (HGA) is an infection caused by the intracellular bacterium . As a tick-borne disease, the public health impact of HGA continues to increase with range expansion of the disease vector. The clinical presentation of HGA is often a non-specific febrile illness. Read More

View Article
November 2018

Clozapine, HIV and neutropenia: a case report.

Ther Adv Psychopharmacol 2018 Dec 19;8(12):365-369. Epub 2018 Nov 19.

Pharmacy Department, Maudsley Hospital, Denmark Hill, London, UK Institute of Pharmaceutical Science, King's College, London, UK.

There is paucity of information on the use of clozapine in patients with HIV. Ethnicity, co-prescribed medications and possible drug-drug interactions are important considerations in evaluating risk of blood dyscrasias during clozapine treatment. Individuals with HIV should not be denied access to the most effective antipsychotic, but a multidisciplinary approach is essential for optimal outcome in such complex patients. Read More

View Article
December 2018

Presence of Immune Complexes of IgG/IgM Bound to B2-glycoprotein I Is Associated With Non-criteria Clinical Manifestations in Patients With Antiphospholipid Syndrome.

Front Immunol 2018 20;9:2644. Epub 2018 Nov 20.

Immunology Department, Hospital 12 de Octubre, Madrid, Spain.

Antiphospholipid syndrome (APS) is an acquired autoimmune disorder defined by the presence of both clinical (thromboembolic events or pregnancy morbidity) and laboratory (antiphospholipid antibodies, aPL) manifestations. Despite their importance, several clinical manifestations strongly associated with APS such as livedo reticularis (LR), thrombocytopenia, sicca-ophthalmic(sicca), heart, or neurological manifestations are not included in the APS clinical classification criteria. Circulating immune complexes (CIC) formed by Beta-2-glycoprotein I (B2GPI) and aPL (B2-CIC) have been described and their presence has been related with thrombotic events. Read More

View Article
November 2018

Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.

J Clin Oncol 2018 Dec 4:JCO1800089. Epub 2018 Dec 4.

Teresa Macarulla, Vall d'Hebrón University Hospital and Vall d'Hebrón Institute of Oncology, Barcelona; Carmen Guillén-Ponce, Hospital Universitario Ramón y Cajal; Andrés Muñoz Martin, Hospital General Universitario Gregorio Marañón; José Martín Valadés, Hospital Universitario Fundación Jiménez Díaz; Javier Sastre, Hospital Clínico Universitario San Carlos; Sofia Perea and Manuel Hidalgo, Centro Nacional de Investigaciones Oncológicas and Centro Integral Oncológico Clara Campal, Madrid; Roberto Pazo-Cid, Hospital Universitario Miguel Servet, Zaragoza; Rafael López, Hospital Clínico de Santiago, Santiago de Compostela; Ruth Vera, Hospital de Navarra, Pamplona; Margarita Reboredo, Hospital Universitario A Coruña, A Coruña; Fernando Rivera, Hospital Universitario Marqués de Valdecilla, Santander; Roberto Díaz Beveridge, Hospital Universitari i Politècnic La Fe, Valencia; Adelaida La Casta, Hospital Universitario Donostia, Donostia; Joaquina Martínez-Galán, Hospital Universitario Virgen de las Nieves, Granada; and Immaculada Ales, Hospital Universitario Carlos Haya, Málaga, Spain.

Purpose: Gemcitabine plus nanoparticle albumin-bound (NAB) paclitaxel (GA) significantly improved survival compared with gemcitabine alone in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) and a Karnofsky performance status (PS) of 70% or greater. Because of the low number of patients with reduced PS, the efficacy of this regimen in fragile patients remains unclear. This study aimed to evaluate the efficacy and tolerability of different GA dosing regimens in patients with a poor PS. Read More

View Article
December 2018

Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study.

J Clin Oncol 2018 Dec 5:JCO1800264. Epub 2018 Dec 5.

Taofeek K. Owonikoko, Gabriel L. Sica, and Suresh S. Ramalingam, Emory University, Atlanta, GA; Suzanne E. Dahlberg, Dana-Farber Cancer Institute, Boston, MA; Lynne I. Wagner, Northwestern University, Chicago; James L. Wade III, Decatur Memorial Hospital, Decatur, IL; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Bradley W. Lash, Guthrie Clinic-Robert Packer Hospital, Sayre; Charu Aggarwal, University of Pennsylvania, Philadelphia, PA; Joseph W. Leach, Metro Minnesota National Cancer Institute Community Oncology Research Program, Minneapolis, MN; and Ticiana B. Leal, University of Wisconsin, Madison, WI.

Purpose: Veliparib, a poly (ADP ribose) polymerase inhibitor, potentiated standard chemotherapy against small-cell lung cancer (SCLC) in preclinical studies. We evaluated the combination of veliparib with cisplatin and etoposide (CE; CE+V) doublet in untreated, extensive-stage SCLC (ES-SCLC).

Materials And Methods: Patients with ES-SCLC, stratified by sex and serum lactate dehydrogenase levels, were randomly assigned to receive four 3-week cycles of CE (75 mg/m intravenously on day 1 and 100 mg/m on days 1 through 3) along with veliparib (100 mg orally twice per day on days 1 through 7) or placebo (CE+P). Read More

View Article
December 2018

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

J Clin Oncol 2018 Dec 6:JCO1801624. Epub 2018 Dec 6.

15 National Surgical Adjuvant Breast and Bowel Project Foundation, Pittsburgh, PA.

Purpose: CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of combination palbociclib plus letrozole as neoadjuvant therapy.

Patients And Methods: Postmenopausal women with ER-positive primary BC and tumors greater than or equal to 2. Read More

View Article
December 2018

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

Lancet Oncol 2018 Nov 30. Epub 2018 Nov 30.

Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.

Background: Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown superior efficacy to chlorambucil monotherapy and are standard first-line treatments in chronic lymphocytic leukaemia. We compared the efficacy of the combination of ibrutinib plus obinutuzumab with chlorambucil plus obinutuzumab in first-line chronic lymphocytic leukaemia or small lymphocytic lymphoma.

Methods: iLLUMINATE is a multicentre, randomised, open-label, phase 3 trial done at 74 academic and community hospitals in Australia, Canada, Israel, New Zealand, Russia, Turkey, the EU, and the USA in patients with previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma, either aged 65 years or older or younger than 65 years with coexisting conditions. Read More

View Article
November 2018

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.

Lancet Oncol 2018 Dec 3. Epub 2018 Dec 3.

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy. Electronic address:

Background: Glioblastoma is a highly vascularised tumour and there are few treatment options after disease recurrence. Regorafenib is an oral multikinase inhibitor of angiogenic, stromal, and oncogenic receptor tyrosine kinases. We aimed to assess the efficacy and safety of regorafenib in the treatment of recurrent glioblastoma. Read More

View Article
December 2018

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Lancet 2018 Dec 3. Epub 2018 Dec 3.

Universitätsmedizin Göttingen, Göttingen, Germany.

Background: Based on the encouraging activity and manageable safety profile observed in a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of CD30-positive peripheral T-cell lymphomas.

Methods: ECHELON-2 is a double-blind, double-dummy, randomised, placebo-controlled, active-comparator phase 3 study. Eligible adults from 132 sites in 17 countries with previously untreated CD30-positive peripheral T-cell lymphomas (targeting 75% with systemic anaplastic large cell lymphoma) were randomly assigned 1:1 to receive either A+CHP or CHOP for six or eight 21-day cycles. Read More

View Article
December 2018

Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.

Ann Pharmacother 2018 Dec 7:1060028018817904. Epub 2018 Dec 7.

3 Houston Methodist Hospital, Houston, TX, USA.

Objective: To review the chemistry, pharmacology, pharmacokinetics, safety, and efficacy of ribociclib (LEE011, Kisqali) in hormone receptor-positive/human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer.

Data Sources: A PubMed search was performed using the terms 'Ribociclib', 'Kisqali', and 'LEE011' between May 2018 and November 2018. References of published articles and reviews were also assessed for additional information. Read More

View Article
December 2018
2.059 Impact Factor

[Cobalamin deficiency in dogs and cats].

Tierarztl Prax Ausg K Kleintiere Heimtiere 2018 Oct 12;46(5):309-314. Epub 2018 Dec 12.

Cobalamin is a member of the B-group of vitamins and a cofactor for metabolic processes like nucleic acid synthesis, amino acid synthesis, and the citric acid cycle. Mammals are unable to synthesize cobalamin and therefore rely on adequate food intake. Cobalamin absorption is a complex process in the stomach, duodenum, and ileum, requiring a functional exocrine pancreas. Read More

View Article
October 2018
4 Reads

Irinotecan plus cisplatin compared with etoposide plus cisplatin in patients with previously untreated extensive-stage small cell lung cancer: A meta-analysis.

J Cancer Res Ther 2018 Dec;14(Supplement):S1076-S1083

Department of Respiratory Diseases, Huaibei Miners General Hospital, Huaibei, Anhui, China.

Objective: To systematically review the effect and safety of irinotecan plus cisplatin (IP) compared with etoposide plus cisplatin (EP) in patients with previously untreated extensive-stage small cell lung cancer (E-SCLC).

Materials And Methods: Databases including PubMed, The Cochrane Library, EMBASE, China National Knowledge Infrastructure, VIP, and WanFang Data were searched for the randomized controlled trials (RCTs) about IP compared with EP in patients with previously untreated E-SCLC from the establishment to June 2016. Two reviewers independently screened literature, extracted data and assessed the methodological quality of included studies. Read More

View Article
December 2018

Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE.

Lupus Sci Med 2018 22;5(1):e000286. Epub 2018 Nov 22.

Research Bioinformatics, MedImmune LLC, Gaithersburg, Maryland, USA.

Objective: Anifrolumab is a fully human immunoglobulin G κ monoclonal antibody specific for subunit 1 of the type I interferon (IFN) α receptor. In a phase IIb study of adults with moderate to severe SLE, anifrolumab treatment demonstrated substantial reductions in multiple clinical endpoints. Here, we evaluated serum proteins and immune cells associated with SLE pathogenesis, type I interferon gene signature (IFNGS) test status and disease activity, and how anifrolumab affected these components. Read More

View Article
November 2018

A comparison of neoadjuvant chemotherapy with gemcitabine versus docetaxel plus cisplatin in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis.

Cancer Manag Res 2018 23;10:6237-6245. Epub 2018 Nov 23.

Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China,

Purpose: To compare the efficacy and safety of neoadjuvant chemotherapy (NACT) with gemcitabine (GEM) vs docetaxel plus cisplatin (CDDP) in locoregionally advanced nasopharyngeal carcinoma (NPC).

Methods: A total of 222 patients with locoregionally advanced NPC between February 2012 and May 2014 in our hospital who received NACT with GEM or docetaxel plus CDDP combined with concurrent chemoradiotherapy (CCRT) were retrospectively analyzed. Fifty-two patients treated with GEM plus CDDP (GP) combined with CCRT were matched with 52 patients who received docetaxel plus CDDP (TP) combined with CCRT. Read More

View Article
November 2018

Associations between the R139C polymorphism and susceptibility to thiopurine-induced leukopenia in Asians: a meta-analysis.

Onco Targets Ther 2018 23;11:8309-8317. Epub 2018 Nov 23.

Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China,

Background And Aim: Despite several studies being conducted to examine the associations between the R139C polymorphism and thiopurine-induced leukopenia in the Asian population, the results remain inconsistent. This meta-analysis determined the risk of thiopurine-induced leukopenia conferred by the R139C polymorphism.

Materials And Methods: All eligible studies published in English up to May 2018 were identified by searching PubMed, Web of Science, Embase, and the Cochrane Library. Read More

View Article
November 2018

Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake.

Onco Targets Ther 2018 23;11:8301-8307. Epub 2018 Nov 23.

Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan,

Background: Oral fluoropyrimidine plus platinum is a standard first-line treatment for advanced gastric cancer (AGC). However, this treatment is problematic for AGC patients with massive ascites or inadequate oral intake. This study aimed at evaluating the efficacy and safety of modified oxaliplatin (L-OHP) with l-leucovorin (l-LV) and bolus/continuous infusion of 5-fluorouracil (5-FU) (mFOLFOX6) regimen for patients with massive ascites or inadequate oral intake. Read More

View Article
November 2018

Incidence and attributes of chemotherapy induced myelotoxicity, anemia and neutropenia in adults with cancer in Nepal: A cross-sectional observational study.

J Oncol Pharm Pract 2018 Dec 11:1078155218817815. Epub 2018 Dec 11.

2 Department of Clinical Oncology, National Academy of Medical Science, Kathmandu, Nepal.

Background: Myelosuppression remains a major toxicity in cancer patients receiving chemotherapy, and is associated with considerable morbidity, mortality and cost.

Objective: The present study aims to investigate the prevalence and incidence of myelotoxicity, anemia and neutropenia in the adult cancer population, and further to determine the factors influencing them.

Methods: This was a cross-sectional observational study conducted at National Academy of Medical Sciences, Bir Hospital, Kathmandu. Read More

View Article
December 2018
1 Read

Efficacy and Safety of Amrubicin in Non-Small-Cell Lung Cancer Patients Beyond Third-Line Therapy.

Oncol Res Treat 2018 Dec 12;42(1-2). Epub 2018 Dec 12.

Background: There are no standard cytotoxic treatments for non-small-cell lung cancer (NSCLC) patients beyond third-line therapy. The purpose of this study was to evaluate the efficacy and safety of amrubicin in pretreated NSCLC patients.

Methods: The records of NSCLC patients who received amrubicin monotherapy as a third or later line of chemotherapy at Shizuoka General Hospital between April 2007 and March 2015 were retrospectively reviewed. Read More

View Article
December 2018
1 Read

A single institutional review of pediatric Bacillus spp. bloodstream infections demonstrates increased incidence among children with cancer.

Pediatr Blood Cancer 2018 Dec 11:e27568. Epub 2018 Dec 11.

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.

Background: Bacillus species are known to cause severe infection in immunocompromised hosts. The incidence of Bacillus bloodstream infections and characteristics of infection among children with cancer or indication for hematopoietic cell transplant (HCT) is unknown.

Methods: We performed a retrospective medical record review of all cases of Bacillus bacteremia between January 1, 2005, and December 31, 2014, at Boston Children's Hospital. Read More

View Article
December 2018

Neutropenia in the age of genetic testing: Advances and challenges.

Am J Hematol 2018 Dec 8. Epub 2018 Dec 8.

Dana Farber and Boston Children's Cancer and Blood Disorders Center, Boston, MA.

Identification of genetic causes of neutropenia informs precision medicine approaches to medical management and treatment. Accurate diagnosis of genetic neutropenia disorders informs treatment options, enables risk stratification, cancer surveillance, and attention to associated medical complications. The rapidly expanding genetic testing options for the evaluation of neutropenia have led to exciting advances but also new challenges. Read More

View Article
December 2018

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.

J Cell Physiol 2018 Dec 10. Epub 2018 Dec 10.

Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Data from 423 human epidermal growth factor receptor 2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. Read More

View Article
December 2018
6 Reads

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial.

Breast Cancer Res Treat 2018 Dec 7. Epub 2018 Dec 7.

Division of Oncology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.

Purpose: To investigate the efficacy of metformin (M) plus chemotherapy versus chemotherapy alone in metastatic breast cancer (MBC).

Methods: Non-diabetic women with HER2-negative MBC were randomized to receive non-pegylated liposomal doxorubicin (NPLD) 60 mg/m + cyclophosphamide (C) 600 mg/m × 8 cycles Q21 days plus M 2000 mg/day (arm A) versus NPLD/C (arm B). The primary endpoint was progression-free survival (PFS). Read More

View Article
December 2018
1 Read

(R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study.

Ann Hematol 2018 Dec 7. Epub 2018 Dec 7.

APHM, service de Neuro-Oncologie, Timone Hospital, CHU Timone, 264 rue saint Pierre, 13005, Marseille, France.

Recurrent primary central nervous system lymphomas (PCNSL) have a very poor prognosis. For young and fit patients, intensive chemotherapy followed by autologous stem cell transplantation could be proposed at relapse. In the other cases (unfit or elderly patients), therapeutic options are limited with no consensual regimen. Read More

View Article
December 2018

[Successful treatment of disseminated fusariosis in a febrile neutropenic patient with combined antifungal therapy of voriconazol plus amphotericin B deoxycholate].

Rev Chilena Infectol 2018 Aug;35(4):448-452

Facultad de Medicina, Universidad de Chile, Chile.

We report a case of a patient with acute lymphoblastic leukemia (ALL), who developed a disseminated infection by Fusarium verticillioides during chemotherapy-induced neutropenia. He was successfully treated only after combination therapy with voriconazole plus amphotericin B deoxycolate was used, but not when these compounds were used in an isolated form. Read More

View Article

[Epidemiology and risk factors for prolonged hospital length of stay in children with leukemia and bacteremia. Cohort study].

Rev Chilena Infectol 2018 ;35(3):233-238

Servicio de Infectologia, Hospital de Pediatría Juan P. Garrahan, Argentina.

Introduction: Bacteremia is a frequent complication in children with cancer, which is associated with greater severity, prolonged hospitalization and mortality. Prolonged hospitalization conditions greater morbidity and risk of acquisition of intranosocomial infections.

Aim: To describe risk factors for prolonged hospital length of stay in children with leukemia and bacteremia. Read More

View Article
January 2018